Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Hiroyuki Horiuchi | Chairman, President & Representative Director | -- | -- | 1962 |
Mr. Tomoyuki Koseki | Chief Officer of Marketing & Sales Division | -- | -- | -- |
Satoshi Murakami | Chief Officer of Regulatory Affairs Division | -- | -- | -- |
Mr. Hironobu Ogura | Chief of Drug Research Centers | -- | -- | -- |
Mr. Masashi Suzudo | MD & Director | -- | -- | 1962 |
Hirofumi Fujii | Corporate Officer | -- | -- | -- |
Mitsuru Watanuki | Head of Research and Development & Director | -- | -- | 1964 |
Masaru Ogawa | Director of Pharmaceutical Affairs Division | -- | -- | -- |
Tatsuhiro Harada | Deputy Chief Officer of R&D Division & Chief of Drug Research Center | -- | -- | -- |
Mr. Keizo Kimura | Chief Officer of Production Division | -- | -- | -- |
Kaken Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,135
Description
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Corporate Governance
Upcoming Events
February 6, 2025 at 4:30 AM UTC
Kaken Pharmaceutical Co., Ltd. Earnings Date
March 28, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available